Psoriatic arthritis
Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com
First In Class, TYK2 Inhibitor FDA Approved for Psoriasis
2022 New ACR Guidance…
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…
1 year 10 months ago
As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).
How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as…
1 year 10 months ago
In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
1 year 10 months ago
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo
Efficacy as early as 2 weeks
No MACE, uveitis, IBD, deaths
@RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi
1 year 10 months ago
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
Podcasts
Canary In A Coal Mine (4.19.2024)
Vasculitis Faculty Panel Q&A
Tuesday Night Rheumatology- Vasculitis Mavens
Poster Hall